The license is exclusive for the territory of Japan and contains rights for future indications

该许可证仅限日本领土使用，并包含未来适应症的权利

Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis encompassing Japan, the US, and EU

Maruho负责在日本进行和承担开发成本，这将与AOB Pharma联合进行，作为涵盖日本、美国和欧盟的全球特应性皮炎第三阶段研究的一部分

The deal includes upfront payments, milestone payments and ongoing royalties.

该协议包括预付款、里程碑付款和持续版税。

CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- AOBiome Therapeutics Inc. ('AOB'), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB's topical biologic B244 (currently preparing for global Phase 3 clinical trials), a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).

马萨诸塞州剑桥市，2024年1月5日/PRNewswire/-AOBiome Therapeutics Inc.（“AOB”）是一家专注于炎症状况的领先临床阶段微生物组公司，今天宣布与Maruho Co.，Ltd.签订独家许可和开发协议，以开发和商业化AOB的局部生物制剂B244（目前正在准备全球3期临床试验），一种皮肤病适应症的治疗方法，包括特应性皮炎，用于外观和瘙痒（瘙痒）。

The license is for all indications treated by the B244 platform..

该许可证适用于B244平台处理的所有适应症。。

Under the license agreement, Maruho will commercialize the product exclusively in Japan. Based on the license agreement, AOB will supply the product to Maruho, and Maruho will make an upfront payment and may also make additional milestone payments depending on achievement of development and commercialization milestones.

根据许可协议，Maruho将在日本独家商业化该产品。根据许可协议，AOB将向Maruho提供产品，Maruho将支付预付款，并可能根据开发和商业化里程碑的实现情况支付额外的里程碑付款。

Maruho also has the rights to AOB's B244 for all additional indications including later stage programs related to inflammation..

Maruho还拥有AOB B244的所有其他适应症的权利，包括与炎症相关的后期计划。。

'B244 offers an opportunity to extend our portfolio for the treatment of Atopic Dermatitis as well as other inflammatory indications. It's unique safety profile and efficacy will allow us to continue our leadership in treating Atopic Dermatitis while improving patients' lives. We look forward to continuing to develop the treatment in collaboration with AOB Pharma.' says Atsushi Sugita, President and CEO of Maruho..

“B244提供了一个机会，可以扩展我们治疗特应性皮炎以及其他炎症适应症的投资组合。它独特的安全性和有效性将使我们能够继续在治疗特应性皮炎方面发挥领导作用，同时改善患者的生活。我们期待着与AOB Pharma合作继续开发这种治疗方法。”Maruho总裁兼首席执行官杉田（AtsushiSugita）表示。。

'We are excited to be partnering with Maruho as they are the leading dermatology player in Japan. We view this as validation of B244's potential to address unmet market needs, not just in Japan but globally. We could not have found a better collaborator as we develop our programs for Japanese patients.

“我们很高兴能与Maruho合作，因为他们是日本领先的皮肤病学家。我们认为这验证了B244解决未满足的市场需求的潜力，不仅在日本，而且在全球范围内。在为日本患者开发项目时，我们找不到更好的合作者。

This model will serve as an example as we fill out our worldwide strategy.' says AOBiome's President & CEO, Todd Krueger..

这种模式将作为我们制定全球战略的一个例子。”AOBiome总裁兼首席执行官托德·克鲁格（ToddKrueger）表示。。

AOB is in the process of planning global Phase 3 studies for B244 in Atopic Dermatitis, for which it aims to start recruiting patients in the second half 2024. The Japanese portion of the Phase 3 trials will be run in Japan by Maruho.

AOB正在计划针对B244特应性皮炎的全球3期研究，其目标是在2024年下半年开始招募患者。第三阶段试验的日本部分将由Maruho在日本进行。

About B244

关于B244

AOB's B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be well-tolerated in clinical studies to date.

AOB的B244平台是一种专利专有的主题配方。一旦部署，B244产生一氧化氮，一种已知调节炎症和血管舒张的信号分子。迄今为止，在临床研究中观察到B244具有良好的耐受性。

Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. See full article at: https://www.nature.com/articles/s41598-021-93299-1.

此外，最近发表的免疫学数据表明，B244可以减少炎症和瘙痒细胞因子IL-4，IL-5，IL-13和IL-31。请参阅全文：https://www.nature.com/articles/s41598-021-93299-1.

About AOB Therapeutics, Inc.

关于AOB Therapeutics，Inc。

AOBiome Therapeutics Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical therapeutics for inflammatory conditions. AOB is advancing a pipeline of multiple, clinical-stage therapeutic candidates. Learn more at AOBPharma.com.

AOBiome Therapeutics Inc.是一家总部位于马萨诸塞州剑桥的生命科学公司，专注于通过开发针对炎症状况的局部治疗剂来改变人类健康。AOB正在推进多个临床阶段治疗候选药物的管道。更多信息，请访问AOBPharma.com。

About Maruho

关于Maruho

Maruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,547 employees (as of the end of September 2022), and net sales were approximately 85.67 billion yen in its fiscal year ended September 30, 2022.

Maruho Co.，Ltd.总部位于大阪，在皮肤病产品的研发、制造和商业化方面处于日本领先地位。Maruho成立于1915年，拥有1547名员工（截至2022年9月底），截至2022年9月30日的财年净销售额约为856.7亿日元。

With the mission 'More smiles, brighter life for you.', Maruho aims to help realize a society where everyone can live with a smile..

以“更多的微笑，为你带来更美好的生活”为使命，Maruho旨在帮助实现一个人人都可以微笑生活的社会。。

For more information, please visit https://www.maruho.co.jp/english/

欲了解更多信息，请访问https://www.maruho.co.jp/english/

Contacts:For Media Inquiries:Jim Hoffman845-417-3487[email protected]

联系人：媒体查询：吉姆·霍夫曼845-417-3487[受电子邮件保护]

SOURCE AOBiome Therapeutics

来源AOBiome Therapeutics